<italic toggle="yes">In Vivo</italic> Emergence of a Novel Protease Inhibitor Resistance Signature in HIV-1 Matrix
ABSTRACT Protease inhibitors (PIs) are the second- and last-line therapy for the majority of HIV-infected patients worldwide. Only around 20% of individuals who fail PI regimens develop major resistance mutations in protease. We sought to explore the role of mutations in gag-pro genotypic and phenot...
Guardado en:
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
American Society for Microbiology
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/7199b87aeca649fba51303efebde939d |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|